- Conditions
- RESPIRATORY SYNCYTIAL VIRUS (RSV)
- Interventions
- RSVpreF, Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 885 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 36
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 143
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Syncytial Viruses, Respiratory Tract Diseases
- Interventions
- RSV Vaccine, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 5,815 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 40
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- ABRYSVO
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 0 Years to 50 Years
- Enrollment
- 1 participant
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV Vaccine (GSK3844766A) unadjuvanted low dose, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted medium dose, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted high dose, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, Placebo (Saline solution)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,053 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 18
- States / cities
- Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV MAT
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Missoula, Montana • Norfolk, Nebraska
- Conditions
- Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, HZ/su vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 11
- States / cities
- Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV-F Particle Vaccine, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3, Investigational RSV vaccine 4, Investigational RSV vaccine 5, Investigational RSV vaccine 6, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Rolling Hills Estates, California • Atlanta, Georgia • Lenexa, Kansas + 2 more
- Conditions
- Respiratory Syncytial Virus Infections+Metapneumovirus
- Interventions
- RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine, RSV/hMPV_W low dose vaccine, RSV/hMPV_W medium dose vaccine, RSV/hMPV_W high dose vaccine, RSV/hMPV_X low dose vaccine, RSV/hMPV_X medium dose vaccine, RSV/hMPV_X high dose vaccine, hMPV_Y low dose vaccine, hMPV_Y medium dose vaccine, hMPV_Y high dose vaccine, hMPV_Z low dose vaccine, hMPV_Z medium dose vaccine, hMPV_Z high dose vaccine, Control vaccine, Placebo
- Biological · Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,456 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Stockbridge, Georgia • Lenexa, Kansas • Seattle, Washington
- Conditions
- RSV Infection
- Interventions
- RSV 6120/∆NS1, RSV 6120/F1/G2/∆NS1, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 59 Months
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 770 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Waterbury, Connecticut • Brooksville, Florida • Immokalee, Florida + 6 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID ΔM2-2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID ΔM2-2 1030s vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 8
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 4 more
- Conditions
- SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
- Interventions
- mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- D46cpΔM2-2 vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Participants
- Interventions
- IVX-A12, Licensed RSV Vaccine
- Biological
- Lead sponsor
- Icosavax, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 5
- States / cities
- Anaheim, California • Rolling Hills Estates, California • Hollywood, Florida + 2 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV-F Vaccine, Phosphate Buffer Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 10
- States / cities
- Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological · Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 12 Months to 79 Years
- Enrollment
- 651 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 31
- States / cities
- La Mesa, California • West Hollywood, California • DeLand, Florida + 28 more
- Conditions
- RSV Infection
- Interventions
- Candidate vaccine, SCB-1019T, AREXVY, placebo
- Biological · Other
- Lead sponsor
- Clover Biopharmaceuticals USA, LLC
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- Prior standard of care receipt of Pfizer's ABRYSVO vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSVpreF Vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Decatur, Georgia + 8 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 10,994 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 93 more
- Conditions
- Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
- Interventions
- RSV preF-based Vaccine, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 11
- States / cities
- Long Beach, California • DeLand, Florida • Miami Lakes, Florida + 7 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV ΔNS2 Δ1313 I1314L Vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Months to 59 Months
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2023
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Laurel, Maryland